The conference brought together more than 150 specialists from the 60 hospitals that make up ITEMAS to share ideas and discuss the challenges of innovation in the healthcare system, focusing on two im...
Read moreEl Servicio de Genética del Hospital Universitario Ramón y Cajal junto con el Laboratorio de Investigación en ELA del Hospital Universitario 12 de Octubre y el Instituto de Investigación CIC nanoG...
Read moreNorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, today an...
Read moreFinal session of the second Biocat Pitch Training Program with helpful tips for catching investors’ eyes. Take note and put them into practice!
Read moreOrigo Biopharma, con sede en el Parque Empresarial de Touro (Galicia), es una biotec fundada en 2017 por Julio Castro y GalChimia, dirigida por Ramon Bosser, CEO y accionista de la compañía. La comp...
Read more In April 2021, Rally Foundation For Childhood Cancer Research invested for the first time in Oncoheroes Biosciences. Today, we are thrilled to announce that Rally Foundation is investing again ba...
Read moreDue to the excellent development of its core business, additional demand generated by the coronavirus pandemic, and several acquisitions, the life science group Sartorius closed fiscal 2021 with excep...
Read moreNorthSea Therapeutics B.V., (‘NST’), a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, announces it has initiated a Phase 1 stud...
Read moreAtlas Molecular Pharma (Atlas), a spin-off of the CIC bioGUNE research centre - a member of the BRTA - and set up with the aim of developing new pharmacological chaperones for the treatment of rare me...
Read moreSpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies, today announced the completion of an oversubscribed €50 million series A financing. The fina...
Read moreNina Capital, an emerging specialist venture capital firm, today announced its second fund, started last fall, eclipsed its target size of EUR40 million in just four months. The fund will be used to c...
Read more